Protara Shares Sink After Pricing $75 Million Public Offering

Dow Jones

2025/12/05

By Connor Hart

Shares of Protara Therapeutics fell after the company priced a $75 million public offering of common stock.

The stock fell 15%, to $5.86, in premarket trading Friday. Through Thursday's close, shares have gained more than 30% so far this year.

The drugmaker said late Thursday that it plans to sell about 13 million shares of its common stock at $5.75 apiece. Protara will also grant underwriters a 30-day option to purchase up to an additional nearly 2 million shares at the offering price, minus discounts and commissions.

Gross proceeds from the offering are expected to be approximately $75 million, and the company intends to use net proceeds to fund the clinical development of investigational cell therapy TARA-002, as well as the development of other clinical programs.

Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

December 05, 2025 06:48 ET (11:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2589891776"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589891776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589891776?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589891776","market":"hk","top_or_hot":-1,"title":"Protara Shares Sink After Pricing $75 Million Public Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Protara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell after the company priced a $75 million public offering of common stock. \n</p>\n<p>\n  The stock fell 15%, to $5.86, in premarket trading Friday. Through Thursday's close, shares have gained more than 30% so far this year. \n</p>\n<p>\n  The drugmaker said late Thursday that it plans to sell about 13 million shares of its common stock at $5.75 apiece. Protara will also grant underwriters a 30-day option to purchase up to an additional nearly 2 million shares at the offering price, minus discounts and commissions. \n</p>\n<p>\n  Gross proceeds from the offering are expected to be approximately $75 million, and the company intends to use net proceeds to fund the clinical development of investigational cell therapy TARA-002, as well as the development of other clinical programs. \n</p>\n<p>\n  Protara may also use the net proceeds from the offering for working capital and other general corporate purposes. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 05, 2025 06:48 ET (11:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protara Shares Sink After Pricing $75 Million Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtara Shares Sink After Pricing $75 Million Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-05 19:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Protara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell after the company priced a $75 million public offering of common stock. \n</p>\n<p>\n  The stock fell 15%, to $5.86, in premarket trading Friday. Through Thursday's close, shares have gained more than 30% so far this year. \n</p>\n<p>\n  The drugmaker said late Thursday that it plans to sell about 13 million shares of its common stock at $5.75 apiece. Protara will also grant underwriters a 30-day option to purchase up to an additional nearly 2 million shares at the offering price, minus discounts and commissions. \n</p>\n<p>\n  Gross proceeds from the offering are expected to be approximately $75 million, and the company intends to use net proceeds to fund the clinical development of investigational cell therapy TARA-002, as well as the development of other clinical programs. \n</p>\n<p>\n  Protara may also use the net proceeds from the offering for working capital and other general corporate purposes. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 05, 2025 06:48 ET (11:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2589891776","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589891776","pubTimestamp":1764935280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Protara Therapeutics fell after the company priced a $75 million public offering of common stock.The stock fell 15%, to $5.86, in premarket trading Friday. Through Thursday's close, shares have gained more than 30% so far this year.The drugmaker said late Thursday that it plans to sell about 13 million shares of its common stock at $5.75 apiece. Protara will also grant underwriters a 30-day option to purchase up to an additional nearly 2 million shares at the offering price, minus discounts and commissions.Gross proceeds from the offering are expected to be approximately $75 million, and the company intends to use net proceeds to fund the clinical development of investigational cell therapy TARA-002, as well as the development of other clinical programs.Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TARA":"ArTara Therapeutics, Inc."},"translate_title":"Protara公开发行7500万美元后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARA":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Protara Therapeutics fell after the company priced a $75 million public offering of common stock. \n\n\n  The stock fell 15%, to $5.86, in premarket trading Friday. Through Thursday's close, shares have gained more than 30% so far this year. \n\n\n  The drugmaker said late Thursday that it plans to sell about 13 million shares of its common stock at $5.75 apiece. Protara will also grant underwriters a 30-day option to purchase up to an additional nearly 2 million shares at the offering price, minus discounts and commissions. \n\n\n  Gross proceeds from the offering are expected to be approximately $75 million, and the company intends to use net proceeds to fund the clinical development of investigational cell therapy TARA-002, as well as the development of other clinical programs. \n\n\n  Protara may also use the net proceeds from the offering for working capital and other general corporate purposes. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 05, 2025 06:48 ET (11:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}